- Home
- APPS vs SION Comparison
APPS vs SION Comparison
Compare APPS & SION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- SION
- Stock Information
- Founded
- APPS 2007
- SION 2019
- Country
- APPS United States
- SION United States
- Employees
- APPS N/A
- SION N/A
- Industry
- APPS Multi-Sector Companies
- SION
- Sector
- APPS Miscellaneous
- SION
- Exchange
- APPS Nasdaq
- SION NYSE
- Market Cap
- APPS 534.2M
- SION 583.9M
- IPO Year
- APPS N/A
- SION 2025
- Fundamental
- Price
- APPS $2.82
- SION $10.16
- Analyst Decision
- APPS Hold
- SION Strong Buy
- Analyst Count
- APPS 4
- SION 1
- Target Price
- APPS $2.38
- SION $32.00
- AVG Volume (30 Days)
- APPS 3.9M
- SION 231.5K
- Earning Date
- APPS 05-27-2025
- SION 03-20-2025
- Dividend Yield
- APPS N/A
- SION N/A
- EPS Growth
- APPS N/A
- SION N/A
- EPS
- APPS N/A
- SION N/A
- Revenue
- APPS $483,577,000.00
- SION N/A
- Revenue This Year
- APPS N/A
- SION N/A
- Revenue Next Year
- APPS $6.49
- SION N/A
- P/E Ratio
- APPS N/A
- SION N/A
- Revenue Growth
- APPS N/A
- SION N/A
- 52 Week Low
- APPS $1.18
- SION $9.37
- 52 Week High
- APPS $6.86
- SION $25.19
- Technical
- Relative Strength Index (RSI)
- APPS 40.39
- SION N/A
- Support Level
- APPS $2.60
- SION N/A
- Resistance Level
- APPS $3.80
- SION N/A
- Average True Range (ATR)
- APPS 0.29
- SION 0.00
- MACD
- APPS -0.07
- SION 0.00
- Stochastic Oscillator
- APPS 17.46
- SION 0.00
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About SION SIONNA THERAPEUTICS INC
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which Heads to insufficient CFTR function.